Table 2:

Characteristics and outcomes of patients admitted to hospital with SARS-CoV-2 infection, stratified by whether or not they live in residential care facilities

VariableNo. (%) of patients from RCFs*
n = 303
No. (%) of patients not from RCFs*
n = 353
Age, yr, mean ± SD83.7 ± 11.063.7 ± 18.3
Age group, yr
 < 502 (0.7)71 (20.1)
 50–5910 (3.3)75 (21.2)
 60–6917 (5.6)54 (15.3)
 70–7951 (16.8)74 (21.0)
 ≥ 80223 (73.6)79 (22.4)
Sex, female182 (60.1)167 (47.3)
Length of symptoms, d, median (IQR) (n = 550)4.0 (2.0–8.0)7.0 (4.0–11.0)
Level of intervention (n = 645)
 147 (15.6)257 (74.7)
 231 (10.3)24 (7.0)
 3166 (55.1)48 (14.0)
 457 (18.9)15 (4.4)
No. of comorbidities
 08 (2.6)95 (26.9)
 139 (12.9)81 (22.9)
 271 (23.4)74 (21.0)
 363 (20.8)48 (13.6)
 ≥ 4122 (40.3)55 (15.6)
Dementia at admission188 (62.0)21 (5.9)
Presence of fever, cough or URTI at admission170 (56.1)252 (71.4)
Hypoxemia (n = 652) at admission121 (39.9)119 (34.1)
Hospital course
 ICU admission14 (4.6)104 (29.5)
 Intubated (n = 132)3 (12.5)66 (61.1)
 Length of intubation, d, median (IQR) (n = 56)9.5 (4.0–15.0)12.5 (8.0–18.0)
 Length of ICU stay, d, median (IQR) (n = 117)4.5 (2.0–15.0)11.0 (5.0–19.0)
 Length of hospital stay (overall), d, median (IQR) (n = 647)14.0 (7.0–26.0)9.0 (5.0–20.0)
 Length of hospital stay (survivor), d, median (IQR) (n = 491)20.0 (10.0–31.0)9.0 (5.0–20.0)
Complications in hospital
 Acute respiratory distress syndrome (n = 654)28 (9.2)69 (19.7)
 Venous thrombotic events (n = 654)9 (3.0)21 (6.0)
 Acute kidney injury (n = 626)60 (20.3)51 (15.5)
 Dialysis (n = 654)0 (0.0)15 (4.3)
 Liver enzyme abnormalities (n = 653)16 (5.3)61 (17.4)
Disposition at discharge
 Discharged190 (62.7)302 (85.6)
 Death111 (36.6)45 (12.7)
 Still admitted2 (0.7)6 (1.7)
Time to death, d, median (IQR) (n = 156)9.0 (5.0–14.0)11.0 (6.0–23.0)
  • Note: ICU = intensive care unit, IQR = interquartile range, RCF = residential care facility, URTI = symptoms of upper respiratory tract infection.

  • * Unless indicated otherwise.

  • Venous thrombotic events refer to pulmonary embolism or deep vein thrombosis.